2013 Archived Content
Bioinformatics in the Genome Era
Understanding the Evolving Role of Bioinformatics in Molecular Medicine
Day 1 | Day 2 | Day 3
Thursday, February 14
7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee
8:00 - 9:40 Plenary Keynote Panel: Emerging Technologies & Industry Perspectives
This session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included. - Read more
9:40 Refreshment Break in the Exhibit Hall with Poster Viewing
10:40 Chairperson’s Remarks
10:45 PANEL DISCUSSION: Nationwide Children’s Presents a Multifaceted Computational Approach to Pediatric Care
Moderator: Andrzej Kloczkowski, Ph.D., Professor, Battelle Center for Mathematical Medicine, The Research Institute at Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University College of Medicine
Saras Saraswathi Ph.D., Postdoctoral Research Associate, Battelle Center for Mathematical Medicine, The Research Institute at Nationwide Children’s Hospital
Richard Ransom, Ph.D., Principal Investigator, Center for Clinical and Translational Research and Faculty, Nephrology and Urology Research Affinity Group, The Research Institute at Nationwide Children’s Hospital
Peter Houghton, Ph.D., Principal Investigator, Hematology/Oncology & Blood and Marrow Transplant (BMT) and Director, Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children’s Hospital
Maqsood Chotani, Ph.D., Principal Investigator, Center for Cardiovascular and Pulmonary Research Heart Center, The Research Institute at Nationwide Children's Hospital
Computational scientists at the Kloczkowski research group, Battelle Center for Mathematical Medicine, have taken the initiative to collaborate with several of the researchers and clinical doctors at The Research Institute (RI) and Nationwide Children’s Hospital (NCH). In the past year, these collaborations with clinical researchers, who conduct studies relating to childhood cancer, nephrotic syndrome, cardiovascular and infectious diseases, have brought synergy and determination to combat childhood diseases. This session will share our experiences and perspectives in applying computational techniques to these studies and working together with scientists coming from widely varying fields of research.
12:15 pm Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own
1:15 Refreshment Break in the Exhibit Hall with Poster Viewing
1:40 Panel Discussion: Implementing the Rapid-Learning Healthcare System for Cancer Care
This session examines the elements of a rapid-learning system for cancer care, including registries and databases and emerging information technology and bioinformatics tools.
Moderator: Marcia Kean, Chairman, Strategic Initiatives, Feinstein Kean Healthcare
~William S. Dalton, Ph.D., M.D., CEO, M2Gen; Director, Personalized Medicine Institute, Moffitt Cancer Center
~Lewis Frey, Ph.D., Assistant Professor, Biomedical Informatics, University of Utah
~Dietrich A. Stephan, Ph.D., President and CEO, Silicon Valley Biosystems, Inc.
~Peter Yu, M.D., Medical Oncologist and Hematologist, Palo Alto Medical Foundation; Chair, Health Information Technology Work Group, The American Society of Clinical Oncology; Co-Chair, Oncology Certification Work Group, Commission for the Certification of Health Information Technology
3:15 Translational Systems Biology: Understanding the Limits of Animal Models as Predictors of Human Biology
Kahn Rhrissorrakrai, Ph.D., Post-Doctoral Researcher, Functional Genomics and Systems Biology, IBM Thomas J. Watson Research Center
Inferring how humans may respond to external stimuli is an essential question in biomedicine. This presentation describes a series of ‘competitive crowd sourcing challenges’ within the SBV IMPROVER project sbvimprover.com that address the issue of translatability between humans and rodents.
3:30 Sponsored Presentation (Opportunity Available)
3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall
(Last Chance to View Posters)
4:30 Chairperson’s Remarks
Manuel C. Peitsch, Ph.D., Vice President, Biological Systems Research, Philip Morris International Research & Development
4:35 FEATURED PRESENTATION: Systems Approaches to Molecular Diagnostics and Perturbed Network Identification
Nathan Price, Ph.D., Associate Professor, Institute for Systems Biology
This presentation discusses broad sources of inter-study variance that can significantly affect reproducibility and accuracy of molecular diagnostics as they move from lab experiment towards the clinic as well as systems appraoches for dealing with these challenges. Also discussed will be network analysis techniques to better link molecular signiatures with underlying biological mechanisms. Such integrations are critical to harnessing the tremendous potential of -omics technologies to revolutionize medicine.
5:05 Robust Statistical Approach for Cancer Research
Svetlana Amirova, Ph.D., Assistant Professor, Mathematics, University of Texas at El Paso
We apply a systems biology approach to study genetic aspects of metabolich pathway regulation for cancer research. To demonstrate universality of this approach, we apply this computational framework to work with biological data motivated by cancer research.
5:35 Predicting Drug Response from Cancer Cell Lines
Adam Margolin, Ph.D., Computational Biology, Sage Bionetworks
6:05 Structural Bioinformatics Analysis Predicts Superior Kinome Selectivity of Clinical p38 MAPK Inhibitor
Li Xing, Ph.D., Senior Principal Scientist, Pfizer
PH-797804 is a p38 kinase inhibitor derived from a racemic mixture as the more potent atropisomer. Structural bioinformatics mining of human kinase genome identified a selectivity motif on the kinase hinge. PH-797804 exhibited high specificity against MAPK and large kinase panels, which translated well to cellular systems. Safety was proven in Phase I clinical trials. Efficacy was achieved in certain human disease population.
6:35 Close of Day
Day 1 | Day 2 | Day 3